ArticleFrontiers in endocrinology2025
ACSL4 predicts rapid kidney function decline in patients with diabetic kidney disease.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Programmed cell death in kidney disease: integrated crosstalk among ferroptosis, pyroptosis, apoptosis, and cuproptosis.Apoptosis : an international journal on programmed cell death · 2026Review
- Emerging Role of Ferroptosis in Diabetes and Associated Complications: When Metabolic Dysregulation Meets Cell Death.Cell proliferation · 2026Review
- Iron-Driven Ferroptosis in Diabetic Kidney Disease: From Molecular Mechanisms to Targeted Therapeutic Translation.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- Ferroptosis regulation by SGLT2 inhibitors: mechanisms and clinical benefits in diabetic kidney disease.Frontiers in pharmacology · 2026Review
- Ferroptosis in Human Diseases: Fundamental Roles and Emerging Therapeutic Perspectives.Antioxidants (Basel, Switzerland) · 2025Review
- The Inflammatory Cell Death in Diabetic Kidney Disease: Integrating Multifactorial Mechanisms into Novel Therapeutics.International journal of molecular sciences · 2025Review
- High glucose-induced PLCG1 histone acetylation to promote ferroptosis by LAMP2A/HSPA8 in a diabetic nephropathy model.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ferroptosis of kidney tubular epithelial cells contributes to the pathogenesis of diabetic kidney disease (DKD). An increase in the enzyme long-chain fatty acid CoA ligase 4 (ACSL4) favors ferroptosis. However, the association between ACSL4 in renal tubules and kidney outcomes of patients with DKD is unknown. Methods: To investigate the predictive property of ACSL4 in rapid kidney function decline in patients with DKD, a retrospective cohort of 72 biopsy-proven DKD patients were enrolled and followed up for a median of 23 months. Tubular expression levels of ACSL4 in the renal biopsy specimens from 72 DKD patients and 12 control subjects were measured using immunohistochemistry staining. The associations between the ACSL4 level and clinical characteristics as well as rapid kidney function decline defined as an estimated glomerular filtration rate (eGFR) slope ≤ -5 ml/min/1.73m Results: ACSL4 was mainly expressed in tubular epithelial cells. The tubular ACSL4 expression levels in the DKD patients were significantly higher than those in the control subjects. ACSL4 was positively correlated with proteinuria and negatively correlated with albumin and hemoglobin at the time of the renal biopsy. During the follow-up time period, the median eGFR slope of these DKD patients was -2.30 ml/min/1.73m Conclusions: ACSL4 was associated with a rapid progression of DKD and may serve as a novel pathological biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.